Dr. Sigal is Tunitas’ founder and Chief Executive Officer. A serial entrepreneur, he has spent over 25 years in the academic, pharmaceutical and biotechnology communities. His biotechnology experience includes President of Trellis Bioscience, EVP of R&D and CSO at Cytokinetics and SVP Drug Discovery for Pharmacopeia, where he was one of Pharmacopeia’s founders. Prior to joining Pharmacopeia, Dr. Sigal held several management positions during a 10-year period with Merck, including Executive Director of Immunology Research. Nolan graduated from Princeton University with an AB in Chemistry. Following completion of an MD/PhD program at the University of Pennsylvania and a pediatric residency, Dr. Sigal was on the faculty at the University of Toronto before moving to Merck. Most of his scientific research focused on understanding the biochemical events involved in the lymphocyte signal transduction.

A founder and CSO of Tunitas, Dr. Saxon is Professor and former Chief of Clinical Immunology and Allergy at the UCLA School of Medicine. Dr. Saxon is a world-renowned expert in the cellular and molecular biology of human allergic disease. In addition to the developing the platforms Tunitas has licensed, Dr. Saxon and his collaborators have made seminal discoveries on the mechanisms that control human allergic antibody (IgE) production and the role of environmental factors in development of the allergic response. Dr. Saxon served as the chairman of the Allergy and Asthma Section of the Immune Tolerance Network for more than a decade and has served in a wide range of capacities for peer reviewed funding organizations across the globe. Andy graduated from Dartmouth College and received his MD degree from Harvard University. Following an internship in internal medicine at UCLA Harbor General Hospital and postdoctoral training in Microbiology/Immunology, he founded the Division of Clinical Immunology/Allergy in the Department of Medicine at UCLA, where he served as Chief of the Division for nearly 30 years.

Dr. King is Tunitas’ Senior VP of Research, responsible for the company’s research and preclinical activities. Previously, he was the Chief Scientific Officer at AnaptysBio where he led a group who developed a novel technology for generating antibody therapeutics, which was successfully used to generate innovative clinical candidate antibodies for a number of pharmaceutical partnerships and for internal development. Dr. King’s tenure in the biotechnology industry includes Medarex, where he led the design and selection of therapeutic antibodies to novel targets in a range of indications and Celltech, where he directed the protein biochemistry and antibody engineering activities that led to the discovery and development of Cimzia®. Dr. King received his B.S. from the University of Warwick and his Ph.D. from the University of Surrey, both in England, and was a Glaxo Group Research postdoctoral fellow.

Ms. Rubinstein brings to Tunitas over 25 years of operational, financial and capital markets experience in life sciences, software and investment banking. As a partner of FLG Partners, Linda’s consulting CFO roles have included ArmaGen, EpiBiome, iPierian (acquired by BMS), Retrotope, True North and Tunitas. Linda has also served as CFO or run finance and administration at public and private companies including PaxVax, Ingenuity Systems (acquired by QIAGEN), Solexa (acquired by Illumina) and ChemoCentryx. Earlier, she served as an investment banker at Lehman Brothers, Scully Brothers & Foss and Merrill Lynch Capital Markets.